iCardiac Applies Automated Approach to Thorough QT Study for a Leading Pharmaceutical Company - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
iCardiac Applies Automated Approach to Thorough QT Study for a Leading Pharmaceutical Company

Source: Company News Release

iCardiac Applies Automated Approach to Thorough QT Study
for a Leading Pharmaceutical Company

Rochester, New York – October 21, 2008 –A leader in advanced cardiac safety analysis announced today that it has completed a highly automated  analysis of ECG data for a leading pharmaceutical firm’s Thorough QT (TQT) study.

iCardiac Technologies, which provides advanced cardiac safety analysis for pharmaceutical and biotech companies in clinical research, analyzed approximately 9.4 million cardiac beats using its proprietary Thorough QT PlusSM  tools . iCardiac’s highly automated approach addresses the high cost and long lead time of cardiac safety trials that use manual measurements exclusively. It is the first solution in the industry to comply with the FDA’s E14 guidance.

“iCardiac was selected by the sponsor for its strong scientific and medical team as well as its advanced ECG analysis capabilities, which have been recognized by top pharmaceutical companies as a way to decrease cost of TQT studies and gain deeper insight into the cardiac safety profile of drugs in development,” said iCardiac’s Co-Founder and Executive Vice President Sasha Latypova.

iCardiac’s highly automated QT technology combines advanced ECG signal processing algorithms developed over the past decade with a robust quality assurance process conducted by cardiologists. It has been validated in studies that show results equivalent to manual measurements performed independently by U.S. board-certified cardiologists.

iCardiac’s highly automated QT technology, which was presented this year to the FDA’s interdisciplinary review team (IRT) meeting, uses sophisticated statistical models and algorithms. It guides cardiologists to those ECGs that require attention and/or adjustment. Using this approach, only a portion of the entire Thorough QT (TQT) dataset requires manual over-reading, thereby generating significant cost savings to sponsors while at the same time providing assurance to the regulators as well as pharmaceutical companies regarding data quality. 

 About iCardiac Technologies
iCardiac Technologies, Inc. develops and implements advanced ECG-based cardiac safety biomarkers and tools. iCardiac’s advanced ECG-based cardiac safety analysis service stems from more than 30 years of research at the University of Rochester, a leading institution for ventricular arrhythmias and cardiac repolarization. iCardiac’s analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement. In addition, it provides Beyond QT,sm a suite of advanced ECG-based cardiac safety markers that deliver a more accurate assessment the cardiac safety profile of drugs in development.  For more information, visit: www.icardiac.com.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here